JP2016501245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501245A5 JP2016501245A5 JP2015545874A JP2015545874A JP2016501245A5 JP 2016501245 A5 JP2016501245 A5 JP 2016501245A5 JP 2015545874 A JP2015545874 A JP 2015545874A JP 2015545874 A JP2015545874 A JP 2015545874A JP 2016501245 A5 JP2016501245 A5 JP 2016501245A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- extracellular matrix
- oral
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 208000025157 Oral disease Diseases 0.000 claims 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 12
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 12
- 210000002744 extracellular matrix Anatomy 0.000 claims 12
- 210000002826 placenta Anatomy 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 102000008186 Collagen Human genes 0.000 claims 5
- 108010035532 Collagen Proteins 0.000 claims 5
- 229920001436 collagen Polymers 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 210000005059 placental tissue Anatomy 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102000007547 Laminin Human genes 0.000 claims 2
- 108010085895 Laminin Proteins 0.000 claims 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical group [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 108010022452 Collagen Type I Proteins 0.000 claims 1
- 102000001187 Collagen Type III Human genes 0.000 claims 1
- 108010069502 Collagen Type III Proteins 0.000 claims 1
- 102000004266 Collagen Type IV Human genes 0.000 claims 1
- 108010042086 Collagen Type IV Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 206010058667 Oral toxicity Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000020670 canker sore Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 231100000026 common toxicity Toxicity 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 229940009976 deoxycholate Drugs 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000002879 macerating effect Effects 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000030194 mouth disease Diseases 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 230000000474 nursing effect Effects 0.000 claims 1
- 229950005751 ocrelizumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 231100000418 oral toxicity Toxicity 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000004991 placental stem cell Anatomy 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229950000815 veltuzumab Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734665P | 2012-12-07 | 2012-12-07 | |
| US61/734,665 | 2012-12-07 | ||
| PCT/US2013/073593 WO2014089440A1 (en) | 2012-12-07 | 2013-12-06 | Treating oral lesions using placental extracellular matrix |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016611A Division JP2019108329A (ja) | 2012-12-07 | 2019-02-01 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501245A JP2016501245A (ja) | 2016-01-18 |
| JP2016501245A5 true JP2016501245A5 (https=) | 2017-01-26 |
Family
ID=50884026
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545874A Pending JP2016501245A (ja) | 2012-12-07 | 2013-12-06 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
| JP2019016611A Withdrawn JP2019108329A (ja) | 2012-12-07 | 2019-02-01 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
| JP2021003902A Withdrawn JP2021073217A (ja) | 2012-12-07 | 2021-01-14 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
| JP2023018047A Pending JP2023065422A (ja) | 2012-12-07 | 2023-02-09 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016611A Withdrawn JP2019108329A (ja) | 2012-12-07 | 2019-02-01 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
| JP2021003902A Withdrawn JP2021073217A (ja) | 2012-12-07 | 2021-01-14 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
| JP2023018047A Pending JP2023065422A (ja) | 2012-12-07 | 2023-02-09 | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150313948A1 (https=) |
| EP (2) | EP3838280A1 (https=) |
| JP (4) | JP2016501245A (https=) |
| CN (2) | CN104955465A (https=) |
| BR (1) | BR112015013125A2 (https=) |
| CA (1) | CA2894160C (https=) |
| HK (1) | HK1215391A1 (https=) |
| RU (2) | RU2015127077A (https=) |
| WO (1) | WO2014089440A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2897625B1 (en) | 2012-09-10 | 2019-10-23 | Wake Forest University Health Sciences | Amniotic membrane and its use in wound healing and tissue engineering constructs |
| BR112017003905A2 (en) * | 2014-08-25 | 2018-03-06 | Hli Cellular Therapeutics, Llc. | extracellular matrix compositions |
| US12083245B2 (en) * | 2014-10-02 | 2024-09-10 | Wake Forest University Health Sciences | Amniotic membrane powder and its use in wound healing and tissue engineering constructs |
| CN110095421B (zh) * | 2019-05-17 | 2022-02-08 | 淮海工学院 | 一种胶原蛋白变性温度的测定方法 |
| CN110975010B (zh) * | 2019-11-25 | 2022-02-15 | 银丰低温医学科技有限公司 | 一种胎盘组织基质材料及其制备方法 |
| CN111494223A (zh) * | 2020-04-22 | 2020-08-07 | 福建汉氏联合干细胞科技有限公司 | 一种胎盘源干细胞漱口修复液 |
| WO2025147712A1 (en) * | 2024-01-05 | 2025-07-10 | Viscus Biologics, Llc | Xenogeneic oral repair compositions and implants thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4185011A (en) | 1978-10-16 | 1980-01-22 | Firma Carl Freudenberg | Process for the production of collagen fibers |
| DE3042860A1 (de) | 1980-11-13 | 1982-06-09 | Heyl & Co Chemisch-Pharmazeutische Fabrik, 1000 Berlin | Kollagenpraeparate, verfahren zu ihrer herstellung und ihre verwendung in der human- und veterinaermedizin |
| FR2516927B1 (fr) | 1981-11-26 | 1986-05-23 | Merieux Fond | Procede de preparation industrielle de materiaux collageniques a partir de tissus placentaires humains, materiaux collageniques humains obtenus, leur application comme biomateriaux |
| US4582640A (en) | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US4642117A (en) | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
| US5436135A (en) | 1985-09-02 | 1995-07-25 | Pasteur Merieux Serums Et Vaccins | New preparation of placenta collagen, their extraction method and their applications |
| US4852640A (en) | 1986-03-28 | 1989-08-01 | Exothermics-Eclipse Inc. | Recuperative heat exchanger |
| US5660692A (en) | 1988-02-24 | 1997-08-26 | Cedars-Sinai Medical Center | Method of crosslinking amino acid-containing polymers using photoactivatable chemical crosslinkers |
| US5008116A (en) | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
| FR2692582B1 (fr) | 1992-06-18 | 1998-09-18 | Flamel Tech Sa | Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux. |
| US5428022A (en) | 1992-07-29 | 1995-06-27 | Collagen Corporation | Composition of low type III content human placental collagen |
| FR2699184B1 (fr) | 1992-12-16 | 1995-03-10 | Flamel Tech Sa | Nouveaux dérivés de collagène, leur procédé d'obtention et leur application à la préparation de biomatériaux. |
| DE69722388T2 (de) | 1996-03-04 | 2004-04-22 | Edwards Lifesciences Corp., Irvine | Nichtpolymere epoxyverbindungen zur vernetzung von biologischem gewebe und daraus hergestellte bioprothesen |
| US5814328A (en) | 1997-01-13 | 1998-09-29 | Gunasekaran; Subramanian | Preparation of collagen using papain and a reducing agent |
| US6117979A (en) | 1997-08-18 | 2000-09-12 | Medtronic, Inc. | Process for making a bioprosthetic device and implants produced therefrom |
| DK1349918T3 (da) | 2000-12-06 | 2014-11-10 | Anthrogenesis Corp | Fremgangsmåde til indsamling af stamceller fra moderkagen |
| EP2316919B1 (en) | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| JP2003119157A (ja) * | 2001-08-06 | 2003-04-23 | Kikuji Yamashita | コラーゲンを含有する洗口剤 |
| JP2005501874A (ja) | 2001-08-31 | 2005-01-20 | ユニバーシティ・オブ・サザン・カリフォルニア | 椎間板及び他のコラーゲン性組織の耐疲労性を向上させ、且つ機械的劣化を低下させるための無毒性架橋試薬の使用 |
| US20030124178A1 (en) * | 2001-12-28 | 2003-07-03 | Haley Jeffrey T. | Soft, adherent, soluble oral patch |
| US20030187515A1 (en) | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
| US20060134201A1 (en) * | 2004-12-16 | 2006-06-22 | Haley Jeffrey T | Collagen troches for treating mouth lesions |
| US7928280B2 (en) * | 2005-07-13 | 2011-04-19 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
| PT2471904T (pt) | 2005-12-29 | 2019-02-25 | Celularity Inc | População de células estaminais placentárias |
| KR20230146124A (ko) * | 2006-10-06 | 2023-10-18 | 셀룰래리티 인코포레이티드 | 천연(텔로펩티드) 태반 콜라겐 조성물 |
| EP2181721A3 (de) * | 2006-11-06 | 2010-05-19 | Lohmann & Rauscher GmbH & Co. KG | Produkt zur Versorgung von Entzündungen, Druckstellen und/oder Aphten im Oralbereich sowie Verwendung eines solchen Produkts |
| EP4559488A3 (en) * | 2007-09-07 | 2025-08-13 | MiMedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
| CA2818813C (en) * | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
-
2013
- 2013-12-06 EP EP20204692.6A patent/EP3838280A1/en not_active Withdrawn
- 2013-12-06 RU RU2015127077A patent/RU2015127077A/ru not_active Application Discontinuation
- 2013-12-06 WO PCT/US2013/073593 patent/WO2014089440A1/en not_active Ceased
- 2013-12-06 CN CN201380071838.3A patent/CN104955465A/zh active Pending
- 2013-12-06 CA CA2894160A patent/CA2894160C/en active Active
- 2013-12-06 HK HK16103392.0A patent/HK1215391A1/zh unknown
- 2013-12-06 US US14/649,990 patent/US20150313948A1/en not_active Abandoned
- 2013-12-06 BR BR112015013125A patent/BR112015013125A2/pt not_active Application Discontinuation
- 2013-12-06 JP JP2015545874A patent/JP2016501245A/ja active Pending
- 2013-12-06 EP EP13861269.2A patent/EP2928481A4/en not_active Withdrawn
- 2013-12-06 RU RU2019101641A patent/RU2019101641A/ru unknown
- 2013-12-06 CN CN202410084412.1A patent/CN117899116A/zh active Pending
-
2019
- 2019-02-01 JP JP2019016611A patent/JP2019108329A/ja not_active Withdrawn
-
2021
- 2021-01-14 JP JP2021003902A patent/JP2021073217A/ja not_active Withdrawn
-
2023
- 2023-02-09 JP JP2023018047A patent/JP2023065422A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501245A5 (https=) | ||
| RU2019101641A (ru) | Лечение поражений полости рта при помощи внеклеточного матрикса плаценты | |
| Costa et al. | Microsurgical reconstruction of the maxilla: algorithm and concepts | |
| Marulli et al. | Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis | |
| Santoro et al. | Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma | |
| Piccoli et al. | Improvement of diaphragmatic performance through orthotopic application of decellularized extracellular matrix patch | |
| Altabas et al. | Endothelial progenitor cells (EPCs) in ageing and age-related diseases: How currently available treatment modalities affect EPC biology, atherosclerosis, and cardiovascular outcomes | |
| BR112013012697A2 (pt) | "método para diminuir expressão, produção ou secreção de um fator angiogênico ou fator hipertrófico ou ambos por células-tronco mesenquimais, métodos para diminuir um efeito inibidor, um efeito deletério, e um efeito de apoptose de células-tronco mesenquimais, método para aumentar um efeito estimulador de células-tronco mesenquimais, composição, e, método para preparar cartilagem em um indivíduo diagnosticado com cartilagem doente ou danificada." | |
| Metzen et al. | Mucormycosis of the head and neck | |
| Xu et al. | Accelerated fibrosis and apoptosis with ageing and in atrial fibrillation: Adaptive responses with maladaptive consequences | |
| Stewart et al. | Bioelectricity and epimorphic regeneration | |
| Levron et al. | Spermatological characters of the pseudophyllidean cestode Bothriocephalus scorpii (Müller, 1776) | |
| Zhang et al. | Resident macrophages as potential therapeutic targets for cardiac ageing and injury | |
| Malik et al. | Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study | |
| Hou et al. | Remifentanil functions in the adaptive protection of cardiac function following ischemia | |
| Lv et al. | Fibroblast Ferroptosis Aggravates Inflammation Response in Dental Pulpitis | |
| Ibarra-Hurtado et al. | Comment to: Chemical components separation with botulinum toxin A: a novel technique to improve primary fascial closure rates of the open abdomen by Zielinski et al. | |
| Jacyniak | Cardiomyocyte Replacement in the Leopard Gecko (Eublepharis macularius): Exploring the Molecular, Cellular, Structural, and Functional Responses Following Injury and Regeneration | |
| Gunes et al. | Comparison of mitoxantrone–melphalan and BEAM conditioning regimens in patients with lymphoma | |
| Marchese et al. | Personal experience on inverted papilloma surgical treatment | |
| FO et al. | Assessment of total leukocyte counts, during menstruation | |
| Elad et al. | Oral effects of nonmyeloablative stem cell transplantation: a prospective observational study. | |
| de OIiveira Raposo | Intracoronary Transfer of Human Umbilical Cord Matrix‐Derived Mesenchymal Stem Cells (HUCM-MSC) for the Preservation of Left Ventricular Function After Acute Myocardial Infarction: Assessment of Invasive Hemodynamic Effects and Potential Underlying Mechanisms in a Large Animal Pre-Clinical Model | |
| Nordquist | Exploring Heart Valve Homeostasis and Repair | |
| Stancu et al. | Case report of canine achantomatous ameloblastoma |